ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1073

Development of a Culturally-Tailored Storytelling Intervention to Improve COVID-19 Vaccine Uptake in Black and Latinx Patients with Autoimmune and Inflammatory Rheumatic Diseases

Maria I. ("Maio") Danila1, Lesley Jackson2, Stephanie Ford3, Mary Wilkenson3, Tiffany Alexander4, Jeroan Allison5, Candace Feldman6, Fred Jenoure7, Jonathan Kay5, Stephenie Lemon8, Kenneth Saag9, Karen Salomon10 and Shilpa Venkatachalam11, 1University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3UAB Division of Clinical Immunology and Rheumatology, Birmingham, AL, 4Community Investigator- AL, Birmingham, AL, 5UMass Chan Medical School, Worcester, MA, 6Brigham and Women's Hospital, Boston, MA, 7Community Investigator- MA, Worcester, MA, 83. Division of Epidemiology, Department of Population and Quantitative Health Sciences, UMass Chan Medical School, Worcester, MA, Worcester, MA, 9The University of Alabama at Birmingham, Birmingham, AL, 10University of Massachusetts Medical School, Shrewsbury, MA, 11Global Healthy Living Foundation, New York, NY

Meeting: ACR Convergence 2025

Keywords: education, patient, health behaviors, quality of care, race/ethnicity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1055–1087) Healthcare Disparities in Rheumatology Posters

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Black and Latinx individuals with autoimmune and inflammatory rheumatic diseases (AIRD) face disproportionately higher risks of severe COVID-19 outcomes. Despite this elevated risk, vaccine uptake remains low in these populations. Interventions that leverage narrative communication and homophily may promote behavior change. We developed a culturally and linguistically tailored, storytelling intervention designed to support a future randomized controlled trial (RCT) of COVID-19 vaccine uptake in Black and Latinx patients with AIRD.

Methods: Intervention development was guided by a conceptual model (Figure 1) created by the study team, which included two community investigators and a representative from a patient advocacy organization. Patients with AIRD from two academic rheumatology clinics in Alabama and Massachusetts and from a patient advocacy organization were recruited as storytellers. Storytellers, selected based on congruence with anticipated background of future RCT participants, signed a media release form and were compensated for their time. Semi-structured in-person or virtual interviews elicited storytellers’ experiences with COVID-19 vaccination, including barriers (e.g., access issues, safety concerns) and facilitators (e.g., trust in the healthcare system, vaccination health benefit) to vaccination. Filmed interviews were split into segments to identify key themes. Each segment was rated from 1 (lowest) to 5 (highest) for emotional authenticity, persuasiveness, content accuracy, and overall impression. The highest-rated segments discussing desired messages were compiled into a draft English-language video, which underwent structured review. A brief introduction featuring a rheumatologist was recorded to provide context for the audience. A professional videographer combined the introduction with the highest-rated storytelling segments, added titles, subtitles, and music to produce the final video. The Spanish-language footage was reviewed and edited to select storytelling segments with the same messages as those in the English-language video (Figure 2).

Results: Black (N&#3f4) and Latinx (N&#3f4) individuals with AIRD participated in structured ~30 minutes interviews in English or Spanish. Eight study team members reviewed and rated 165 minutes of footage in English and six Spanish-fluent study team members reviewed and rated 131 minutes of Spanish-language footage. The ~10 minutes draft English-language video was edited to ~4 minutes after the second round of review. Table 1 shows key broad themes, subthemes, and second round of review rating scores for each clip selected for the final videos. Both English and Spanish-language videos were edited to ~4 minutes (Figure 2).

Conclusion: Guided by the storytelling narrative communication theory and a structured iterative editing process, we produced two culturally tailored storytelling videos in English and Spanish that can be tested, together with patient navigation, as an approach to improve COVID-19 vaccination rates in Black and Latinx individuals with AIRD. Our robust approach to intervention development is scalable and adaptable to other preventative care interventions.

Supporting image 1Table 1. Key overarching themes, subthemes, and rating scores for each clip represented in final storytelling video.

Supporting image 2Figure 1. Conceptual Model for the Multi-modal Intervention Design.

Supporting image 3Figure 2: Storytellers and final topics chosen to promote the updated COVID vaccination in Black and Latinx patients with AIRD in English and Spanish.


Disclosures: M. Danila: Boehringer-Ingelheim, 2, Pfizer, 5; L. Jackson: None; S. Ford: None; M. Wilkenson: None; T. Alexander: None; J. Allison: None; C. Feldman: American College of Rheumatology, 2, Arthritis Foundation, 5, 12, Task Force Member, Bain Capital, 2, Bristol-Myers Squibb Foundation, 5, Harvard Pilgrim, 2, Lupus Foundation of America, 1, 12, Associate Editor, Medical-Scientific Advisory Board Member, OM1, Inc., 2; F. Jenoure: None; J. Kay: Biogen, 5, Celltrion, Inc., 2, Gate Bioscience, 2, Immunitas Therapeutics, 2, Immunovant, Inc., 2, Istesso, Ltd, 2, Kolon TissueGeje, Inc, 1, Organon, LLC, 2, Sana Biotechnology, Inc., 2, Santa Ana Bio, Inc., 2, Spyre Therapeutics, 2, Wolters Kluwer NV, 9; S. Lemon: Merck/MSD, 5; K. Saag: Arthrosi, 2, 5, Atom Bioscience, 2, Cyrstalys, 2, Inventis, 5, LG Pharma, 2, 5, Novo Nordisc, 2, Olatec, 5, Shanton, 2, Sobi, 2; K. Salomon: None; S. Venkatachalam: None.

To cite this abstract in AMA style:

Danila M, Jackson L, Ford S, Wilkenson M, Alexander T, Allison J, Feldman C, Jenoure F, Kay J, Lemon S, Saag K, Salomon K, Venkatachalam S. Development of a Culturally-Tailored Storytelling Intervention to Improve COVID-19 Vaccine Uptake in Black and Latinx Patients with Autoimmune and Inflammatory Rheumatic Diseases [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/development-of-a-culturally-tailored-storytelling-intervention-to-improve-covid-19-vaccine-uptake-in-black-and-latinx-patients-with-autoimmune-and-inflammatory-rheumatic-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-a-culturally-tailored-storytelling-intervention-to-improve-covid-19-vaccine-uptake-in-black-and-latinx-patients-with-autoimmune-and-inflammatory-rheumatic-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology